Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Biomea Fusion, Inc.

BMEA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.42

▲ +3.65%

Market Cap $102.93M · Vol 140.70K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$102.93M

Micro Cap

Div Yield

N/A

EPS Growth

+33.89%

YoY

RSI (14)

34.41

Momentum

Beta

-0.24

vs Market

52W High

$2.23

36.32% below

52W Low

$0.88

61.36% above

Volume

140.70K

Avg 327.39K

P/B

3.03

Price-to-book

ROE

-152.35%

Return on equity

Free Float

92.85%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Biomea Fusion, Inc. (BMEA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BMEA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+11.81%

-23.04%

+8.40%

-23.24%

YTD

+14.52%

-20.67%

-88.28%

-88.37%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-61,797,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-152.35%
ROA · ROIC	-89.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.03
P/FCF	N/A
EPS Growth	+33.89%
Outstanding Shares	72.48M

Technical Indicators

50-Day SMA	$1.51
200-Day SMA	$1.41
RSI (14)	34.41
Beta	-0.24
52-Week High	$2.23
52-Week Low	$0.88

Volume Today	140.70K
Avg Daily Volume (30D)	327.39K
Relative Volume	0.43x
Volatility (10D)	55.36
Volatility (30D)	86.78
Free Float	92.85%

Analyst Consensus

BUY

Current Price $1.42

Mean Target $7.00

52W Low$0.88 52W High$2.23

Current

Target

$0.88 $2.23

Current Analyst target

+392.96% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00YS4WDD8

ISINUS09077A1060

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.56% ONC BeOne Medicines AG +1.24% 068270.KS Celltrion, Inc. -2.13% MEDP Medpace Holdings, Inc. +1.55% ABVX Abivax SA -1.01%

Company Profile

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies, including icovamenib and BMF-650, for diabetes and obesity, with research activities focused on the biology of metabolic diseases. Its covalent small molecule drug is a synthetic compound that forms a permanent bond with its target protein. The Company’s clinical candidate, icovamenib, is an investigational oral small molecule that reversibly downmodulates menin, a transcriptional regulator involved in beta-cell biology. Its Phase 2 clinical development includes type 1 and type 2 diabetes, obesity, and combination with GLP-1 receptor agonist therapies. The Company’s second product candidate, BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for the treatment of diabetes and obesity.